Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Breast 2Thoracic 1Sarcoma 1Other neoplasm 1NET 1Myeloid 1Endocrine 1CNS 1

Conditions

Myelodysplastic Syndromes 1

Interventions

Cytarabine 30fludarabine phosphate 19Specimen Handling 15Cyclophosphamide 15Biopsy 14Peripheral Blood Stem Cell Transplantation 13Busulfan 13Imatinib Mesylate 12Etoposide 12Filgrastim 11Decitabine 11Azacitidine 11Methotrexate 10Idarubicin 10Daunorubicin 10Cyclosporine 9X-Rays 8Tacrolimus 8Antilymphocyte Serum 8tipifarnib 7Vorinostat 7Stem Cell Transplantation 7Radiotherapy 7Magnetic Resonance Spectroscopy 7fludarabine 6decitabine and cedazuridine drug combination 6Phantoms, Imaging 6Topotecan 5Prednisone 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Photons × Myeloid × Clear all
NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡